Lipella Pharmaceuticals Inc.
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $536.4K | $449.6K | $184.2K | $259.3K |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $3.6M | $3.0M | $2.5M | $1.5M |
| SG&A Expense | $2.0M | $2.2M | $226.2K | $718.4K |
| Operating Income | $-5.1M | $-4.7M | $-2.6M | $-1.9M |
| Operating Margin | -947.2% | -1,055.6% | -1,406.3% | -738.7% |
| Interest Expense | — | $10.8K | $9.6K | $6.8K |
| Pretax Income | $-5.0M | $-4.6M | $-2.6M | $-1.9M |
| Income Tax Expense | — | — | — | — |
| Net Income | $-5.0M | $-4.6M | $-2.6M | $-1.9M |
| Net Margin | -935.2% | -1,027.3% | -1,410.6% | -719.3% |
| EPS (Basic) | $-4.79 | $-6.16 | $-0.64 | $-0.55 |
| EPS (Diluted) | $-4.79 | $-6.16 | $-0.64 | $-0.55 |
| Shares Outstanding (Basic) | 1.0M | 750.4K | 4.1M | 3.4M |
| Shares Outstanding (Diluted) | 1.0M | 750.4K | 4.1M | 3.4M |
| Dividends Per Share | — | — | — | — |